Invasion patterns in brain metastases of solid cancers

Neuro-Oncology

Volumn 15, Issue 12, 2013, Pages 1664-1672

  Berghoff, Anna S ^a,b   Rajky, Orsolya ^a,b   Winkler, Frank ^c   Bartsch, Rupert ^a,b   Furtner, Julia ^a   Hainfellner, Johannes A ^b   Goodman, Simon L ^d   Weller, Michael ^e   Schittenhelm, Jens ^f   Preusser, Matthias ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Austrian Breast and Colorectal Cancer Study Group   (Austria)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d Merck Serono GmbH   (Germany)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Adhesion molecules; Brain metastases; Cadherin; Integrin; Invasion

Indexed keywords

ALPHAVBETA5 INTEGRIN; ALPHAVBETA6 INTEGRIN; ALPHAVBETA8 INTEGRIN; BETA3 INTEGRIN; INTEGRIN; NERVE CELL ADHESION MOLECULE; UNCLASSIFIED DRUG; UVOMORULIN; VITRONECTIN RECEPTOR;

ADULT; AGED; ARTICLE; AUTOPSY; BRAIN METASTASIS; BREAST CANCER; CANCER PATIENT; COLORECTAL CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; LUNG CANCER; MALE; MELANOMA; MIDDLE AGED; PROTEIN EXPRESSION; SOLID TUMOR; STEREOTACTIC RADIOSURGERY; TUMOR INVASION; VERY ELDERLY;

ADHESION MOLECULES; BRAIN METASTASES; CADHERIN; INTEGRIN; INVASION;

ADULT; AGED; AGED, 80 AND OVER; AUTOPSY; BRAIN NEOPLASMS; CADHERINS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; INTEGRINS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84891867198     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not112     Document Type: Article

References (32)

1. Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology. J Neurooncol. 2005;75(1):5-14.
2. Gaspar LE, MehtaMP, Patchell RA, et al. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: A systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96(1):17-32.
3. Kalkanis SN, Kondziolka D, Gaspar LE, et al. The role of surgical resection in the management of newly diagnosed brain metastases: A systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96(1):33-43.
4. Linskey ME, Andrews DW, Asher AL, et al. The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: A systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96(1):45-68.
5. Wesseling P, von Deimling A, Aldape K. Metastatic Tumours of the CNS. 4th ed. Lyons, France: IARC Press; 2007.
6. Baumert BG, Rutten I, Dehing-Oberije C, et al. A pathology-based substrate for target definition in radiosurgery of brain metastases. Int J Radiat Oncol Biol Phys. 2006;66(1):187-194.
7. Neves S, Mazal PR, Wanschitz J, et al. Pseudogliomatous growth pattern of anaplastic small cell carcinomas metastatic to the brain. Clin Neuropathol. 2001;20(1):38-42.
8. Spanberger T, Berghoff AS, Dinhof C, et al. Extent of peritumoral brain edema correlates with prognosis, tumoral growth pattern, HIF1a expression and angiogenic activity in patients with single brain metastases. Clin Exp Metastasis. 2013;30(4):357-368.
9. McPherson CM,Suki D, Feiz-Erfan I, et al. Adjuvant whole-brain radiation therapy after surgical resection of single brain metastases. Neuro Oncol. 2010;12(7):711-719.
10. Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell. 2011;147(5):992-1009.
11. Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2010;10(1):9-22.
12. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol. 2004;5(10):816-826.
13. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer. 2002;2(2):91-100.
14. Bonneh-Barkay D, Wiley CA. Brain extracellular matrix in neurodegeneration. Brain Pathol. 2009;19(4):573-585.
15. Mazal PR, Czech T, Sedivy R, et al. Prognostic relevance of intracytoplasmic cytokeratin pattern, hormone expression profile, and cell proliferation in pituitary adenomas of akromegalic patients. Clin Neuropathol. 2001;20(4):163-171.
16. Gelpi E, Popovic M, Preusser M, Budka H, Hainfellner J. Pleomorphic xanthoastrocytoma with anaplastic features presenting withoutGFAPimmunoreactivity: implications for differential diagnosis. Neuropathology. 2005;25(3):241-246.
17. Birner P, Piribauer M, Fischer I, et al. Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes. Brain Pathol. 2003;13(2):133-143.
18. Goodman SL, Grote HJ, Wilm C. Matched rabbit monoclonal antibodies against alphav-series integrins reveal a novel alphavbeta3-LIBS epitope, and permit routine staining of archival paraffin samples of human tumors. Biol Open. 2012;1(4):329-340.
19. Schittenhelm J, Schwab EI, Sperveslage J, et al. Longitudinal Expression analysis of alphav integrins in human gliomas reveals upregulation of integrin alphavbeta3 as a negative prognostic factor. J Neuropathol Exp Neurol. 2013;72(3):194-210.
20. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005;97(9):643-655.
21. Hirsch FR, Varella-Garcia M, Bunn PA, Jr., et al., Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol. 2003;21(20):3798-3807.
22. Bender R, Lange S. Adjusting for multiple testing - when and how? J Clin Epidemiol. 2001;54(4):343-349.
23. Bandyopadhyay A, Raghavan S. Defining the role of integrin alphavbeta6 in cancer. Curr Drug Targets. 2009;10(7):645-652.
24. Kienast Y, von Baumgarten L, Fuhrmann M, et al. Real-time imaging reveals the single steps of brain metastasis formation. Nat Med. 2010;16(1):116-122.
25. Dome B, Paku S, Somlai B, Timar J. Vascularization of cutaneous melanoma involves vessel co-option and has clinical significance. J Pathol. 2002;197(3):355-362.
26. LeendersWP, Kusters B,Verrijp K, et al. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin Cancer Res. 2004;10(18 Pt 1):6222-6230.
27. Wild-Bode C, Weller M, Rimner A, Dichgans J, Wick W. Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res. 2001; 61(6):2744-2750.
28. Monnier Y, Farmer P, Bieler G, et al. CYR61 and alphaVbeta5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma. Cancer Res. 2008;68(18):7323-7331.
29. Goodman SL, Picard M. Integrins as therapeutic targets. Trends Pharmacol Sci. 2012;33(7):405-412.
30. Manegold C, Vansteenkiste J, Cardenal F, et al. Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer. Invest New Drugs. 2013;31(1): 175-182.
31. O'Day S, Pavlick A, Loquai C, et al. A randomised, phase II study of intetumumab, an anti-alphav-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br J Cancer. 2011;105(3):346-352.
32. Wu YJ, Muldoon LL, Gahramanov S, Kraemer DF, Marshall DJ, Neuwelt EA. Targeting alphaV-integrins decreased metastasis and increased survival in a nude rat breast cancer brain metastasis model. J Neurooncol. 2012;110(1):27-36.